1. Home
  2. ZTS vs KVUE Comparison

ZTS vs KVUE Comparison

Compare ZTS & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zoetis Inc.

ZTS

Zoetis Inc.

SELL

Current Price

$75.50

Market Cap

32.5B

Sector

Health Care

ML Signal

SELL

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$18.78

Market Cap

36.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZTS
KVUE
Founded
1952
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Chemicals
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
32.5B
36.9B
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
ZTS
KVUE
Price
$75.50
$18.78
Analyst Decision
Buy
Buy
Analyst Count
12
11
Target Price
$154.18
$19.45
AVG Volume (30 Days)
4.8M
17.8M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
1.86%
4.82%
EPS Growth
10.05
40.74
EPS
3.08
0.48
Revenue
$9,467,000,000.00
$15,124,000,000.00
Revenue This Year
$5.63
$4.85
Revenue Next Year
$4.77
$2.63
P/E Ratio
$24.82
$39.60
Revenue Growth
2.28
N/A
52 Week Low
$71.00
$14.02
52 Week High
$149.75
$20.13

Technical Indicators

Market Signals
Indicator
ZTS
KVUE
Relative Strength Index (RSI) 50.81 48.58
Support Level $73.02 $18.67
Resistance Level $78.74 $19.15
Average True Range (ATR) 2.21 0.31
MACD 0.14 -0.02
Stochastic Oscillator 70.32 35.29

Price Performance

Historical Comparison
ZTS
KVUE

About ZTS Zoetis Inc.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Share on Social Networks: